Impact of elosulfase alfa in patients with Morquio syndrome type A who have limited ambulation: An open-label, phase 2 study

2016 ◽  
Vol 117 (2) ◽  
pp. S55
Author(s):  
Paul R. Harmatz ◽  
Andrea Jester ◽  
Eugen Mengel ◽  
Marsha Treadwell ◽  
Barbara K. Burton ◽  
...  
Keyword(s):  
Type A ◽  
Syndrome Type ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Morquio Syndrome ◽  
Elosulfase Alfa

scholarly journals Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study

2016 ◽  
Vol 173 (2) ◽  
pp. 375-383 ◽  
Author(s):  
Paul R. Harmatz ◽  
Eugen Mengel ◽  
Tarekegn Geberhiwot ◽  
Nicole Muschol ◽  
Christian J. Hendriksz ◽  
...  
Keyword(s):  
Phase 2 ◽  
Open Label ◽  
Morquio A ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Morquio A Syndrome ◽  
Elosulfase Alfa

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

2011 ◽  
Vol 17 (21) ◽  
pp. 6905-6913 ◽  
Author(s):  
Richard S. Finn ◽  
Carmelo Bengala ◽  
Nuhad Ibrahim ◽  
Henri Roché ◽  
Joseph Sparano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Single Agent ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

The patient experience of elosulfase alfa treatment for MPS IVA (Morquio syndrome type A): beyond traditional measures

2017 ◽  
Vol 120 (1-2) ◽  
pp. S70-S71
Author(s):  
James Jarrett ◽  
Mohit Jain ◽  
Charlotte Roberts ◽  
Alexandra Morrison
Keyword(s):  
Patient Experience ◽  
Type A ◽  
Syndrome Type ◽  
Mps Iva ◽  
Morquio Syndrome ◽  
Elosulfase Alfa

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2 -amplified early stage breast cancer: a single-group, open-label, phase 2 study

2013 ◽  
Vol 14 (11) ◽  
pp. 1121-1128 ◽  
Author(s):  
Stephen E Jones ◽  
Rufus Collea ◽  
Devchand Paul ◽  
Scot Sedlacek ◽  
Anne M Favret ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Phase 2 ◽  
Single Group ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document